Techno Drugs Ltd. announcements
59 Dhaka Stock Exchange announcements for Techno Drugs Ltd. (TECHNODRUG) since 2024: results, dividends, board meetings, AGMs, record dates and other price-sensitive information. Showing 2025 (21).
- Credit Rating Result
Emerging Credit Rating Limited (ECRL) has affirmed surveillance rating of the Company as "BBB" in the long term and "ST-3" in the short term along with a Stable outlook based on annual audited financial statements up to June 30, 2025, quarterly unaudited financial statements up to September 30, 2025, and other relevant quantitative as well as qualitative information up to the date of rating.
- Emphasis of Matter
The auditor of the company has given the "Emphasis of Matter" paragraph in the Auditor's Report of the company for the year ended on 30 June 2025. To view the details, please visit: https://www.dsebd.org/Auditors_opinion/2025/TECHNODRUG2025.pdf
- Resumption after Record Date
Trading of the shares of the company will resume on 20.11.2025.
- Suspension for Record Date
Trading of the shares of the company will remain suspended on record date i.e., 19.11.2025.
- Q1 Financials
(Q1 Un-audited): EPS was Tk. 0.47 for July-September 2025 as against Tk. 0.63 for July-September 2024; NOCFPS was Tk. 0.15 for July-September 2025 as against Tk. 0.23 for July-September 2024. NAV per share (with revaluation) was Tk. 31.04 as on September 30, 2025 and Tk. 30.58 as on June 30, 2025; NAV per share (without revaluation) was Tk. 27.35 as on September 30, 2025 and Tk. 26.88 as on June 30, 2025. (cont.) (cont. news of TECHNODRUG): The company's EPS and NOCFPS have decreased mainly due to lower sales revenue and increase financial expenses, higher cash out flow for payments to suppliers, lower collection from A/c receivable during the quarter. In addition, increasing ordinary shares by IPO also played a part. Altogether resulted in reducing EPS and Cash Flow from operation in the first quarter. (end)
- Spot News
Trading of the shares of the company will be allowed only in the Spot Market and Block transaction will also be settled as per spot settlement cycle with cum benefit from 17.11.2025 to 18.11.2025 and trading of the shares will remain suspended on record date i.e., 19.11.2025.
- Board Meeting schedule under LR 16(1)
As per Regulation 16(1) of the Dhaka Stock Exchange (Listing) Regulations, 2015, the Company has informed that a meeting of the Board of Directors will be held on November 13, 2025 at 3:30 PM to consider, among others, Un-audited financial statements of the Company for the First Quarter (Q1) period ended September 30, 2025.
- Auditor's report regarding status of IPO Proceeds utilization
Techno Drugs Limited submitted auditor's report regarding "Status of IPO (Initial Public Offering) Proceeds utilization statement" for the quarter ended September?30,?2025. To view the details, please visit: https://www.dsebd.org/Auditors_opinion/2025/Techno-Drugs-Ltd-2025.pdf
- Dividend Declaration
The Board of Directors has recommended 10% Cash Dividend for general shareholders excluding Sponsors and Directors for the year ended June 30, 2025. The Sponsors and Directors hold 82,776,200 shares out of the total 131,998,188 shares of the company and Cash Dividend payable to the General Shareholders is Tk. 49,221,988.00. Date of AGM: 24.12.2025, Time: 10:00 AM; (cont.1) (Cont. News of TECHNODRUG): The Company has also reported EPS of Tk. 1.76, NAV per share of Tk. 30.58 (with revaluation), NAV per share of Tk. 26.88 (without revaluation) and NOCFPS of Tk. 1.43 for the year ended June 30, 2025 as against Tk. 2.94, Tk. 33.50 (with revaluation), 28.33 (without revaluation) and Tk. 4.48 respectively for the year ended June 30, 2024. (end) (Cont. News of TECHNODRUG): Venue/Mode of AGM: Hybrid System in combination of Physical Presence at Institution of Diploma Engineers, l60/A, Kakrail VIP Road, Dhaka 1000 and Digital Platform through the link: https:// technodrug.hybridagmbd.net. Record Date: 19.11.2025. (cont.2)
- Price Limit Open
There will be no price limit on the trading of the shares of the Company today (29.10.2025) following its corporate declaration.
- Board Meeting schedule under LR 19(1)
As per Regulation 19(1) of the Dhaka Stock Exchange (Listing) Regulations, 2015, the Company has informed that a meeting of the Board of Directors will be held on October 28, 2025 at 3:00 PM to consider, among others, audited financial statements of the Company for the year ended on June 30, 2025.
- Regarding contraceptive implants (single rod)
The company has informed that it has been producing contraceptive implants (two rod) since 2019 and these products are dedicated to supplying the Ministry of Family Planning of Bangladesh. Additionally, on 23rd September 2025, the company successfully completed the trial run for production of implants (single rod) along with previous contraceptive implants (two rod) and both products will be supplied to the government, subject to getting the tender.
- Auditor's report regarding status of IPO Proceeds utilization
Techno Drugs Ltd. submitted auditor's report regarding status of IPO (Initial Public Offering) Proceeds utilization statement for the quarter ended on June 30, 2025. To view the details, please visit: https://www.dsebd.org/Auditors_opinion/2025/Techno%20Drugs%20Ltd_2025.pdf
- Auditor's report regarding status of IPO Proceeds utilization
Techno Drugs Limited submitted auditor's report regarding "Status of IPO (Initial Public Offering) Proceeds utilization statement" for the quarter ended 31 March, 2025. To view the details, please visit: https://www.dsebd.org/Auditors_opinion/2025/Techno%20Drugs%20Ltd_25.pdf
- Q3 Financials
(Q3 Un-audited): EPS was Tk. 0.33 for January-March 2025 as against Tk. 0.42 for January-March 2024; EPS was Tk. 1.41 for July 2024-March 2025 as against Tk. 2.58 for July 2023-March 2024. NOCFPS was Tk. 0.15 for July 2024-March 2025 as against Tk. 2.94 for July 2023-March 2024. NAV per share (with revaluation) was Tk. 30.24 as on March 31, 2025 and Tk. 33.50 as on June 30, 2024. NAV per share (without revaluation) was Tk. 26.55 as on March 31, 2025 and Tk. 28.33 as on June 30, 2024. (cont.1) (Cont. news of TECHNODRUG): The reason behind of low sales value is Government did not procure as much as they did in the last year. The company mostly sell to contraceptive items to Government and Government is their large buyer of these items. In addition, the company recently issued shares for IPO, resulting in increasing 3,78,40,788 shares. These increased shares also played a part. Altogether resulted in reducing EPS, Cash Flow from Operation and NAV in this period. (end) (Cont. news of TECHNODRUG): The company's EPS, Cash Flow from Operation and NAV are 1.41, 0.15 and 30.24 respectively in July-24 to March-25 (9 month) against 2.58, 2.94 and 33.50 in the July-23 to March-24 (9 month) of previous period. So, there is significant deviation in EPS, Cash Flow from Operation and NAV. This is because sales have come down to Tk. 259.39 crore from Tk. 308.04 crore in the current period than previous period. (cont.2)
- Board Meeting schedule under LR 16(1)
As per Regulation 16(1) of the Dhaka Stock Exchange (Listing) Regulations, 2015, the Company has informed that a meeting of the Board of Directors will be held on April 29, 2025 at 4:30 PM to consider, among others, un-audited financial statements of the Company for the Third Quarter (Q3) period ended March 31, 2025.
- Auditor's report regarding status of IPO Proceeds utilization
Techno Drugs Ltd. submitted auditor's report regarding status of IPO (Initial Public Offering) Proceeds utilization statement for the quarter ended December 31, 2024. To view the details, please visit: https://www.dsebd.org/Auditors_opinion/2024/TECHNODRUGS_2024.pdf
- Dividend Disbursement
The Company has informed that it has disbursed the Cash Dividend for the year ended June 30, 2024 to the respective shareholders.
- Category Change
The Company will be placed in 'A' category from existing 'N' category with effect from February 04, 2025 as the Company has reported disbursement of 12% Cash Dividend for the year ended June 30, 2024.
- Q2 Financials
(Q2 Un-audited): Basic EPS was Tk. 0.48 for October-December 2024 as against Tk. 1.07 for October-December 2023; EPS was Tk. 1.08 for July-December 2024 as against Tk. 2.16 for July-December 2023. NOCFPS was Tk. 0.19 for July-December 2024 as against Tk. 1.23 for July-December 2023. NAV per share (with revaluation) was Tk. 29.91 as on December 31, 2024 and Tk. 33.50 as on June 30, 2024. NAV per share (without revaluation) was Tk. 26.22 as on December 31, 2024 and Tk. 28.33 as on June 30, 2024. (cont.1) (cont. news of TECHNODRUG): The reason behind of low sales value is Government did not procure as much as they did in the last year. The company mostly sell to contraceptive items to Government and Government is their large buyer of these items. In addition, the company recently issued shares for IPO, resulting in increasing 3,78,40,788 shares. These increased shares also played a part. Altogether resulted in reducing EPS, Cash Flow from Operation and NAV in the second quarter. (end) (cont. news of TECHNODRUG): Reasons for significant variance: The company's EPS, Cash Flow from Operation and NAV are 1.08, 0.19 and 29.91 respectively in July to December 2024 against 2.16, 1.23 and 33.50 in the previous period July to December 2023. So, there is significant deviation in EPS, Cash Flow from Operation and NAV. This is because sales have come down to Tk. 193 crore from Tk. 255 crore in the current period than the previous period. (cont.2)
- Board Meeting schedule under LR 16(1)
As per Regulation 16(1) of the Dhaka Stock Exchange (Listing) Regulations, 2015, the Company has informed that a meeting of the Board of Directors will be held on January 30, 2025 at 4:30 PM to consider, among others, un-audited financial statements of the Company for the Second Quarter (Q2) period ended December 31, 2024.
Source: Dhaka Stock Exchange announcements. Some posts before 2014 have no title, and 2014–2020 coverage is incomplete.